Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose
about
New drugs in psychiatry: focus on new pharmacological targets.Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model.Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology.Commentary on "The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis".The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.Emerging Evidence for Cannabis' Role in Opioid Use Disorder
P2860
Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Cannabidiol is a partial agoni ...... ts antipsychotic clinical dose
@en
Cannabidiol is a partial agoni ...... ts antipsychotic clinical dose
@nl
type
label
Cannabidiol is a partial agoni ...... ts antipsychotic clinical dose
@en
Cannabidiol is a partial agoni ...... ts antipsychotic clinical dose
@nl
prefLabel
Cannabidiol is a partial agoni ...... ts antipsychotic clinical dose
@en
Cannabidiol is a partial agoni ...... ts antipsychotic clinical dose
@nl
P2860
P356
P1476
Cannabidiol is a partial agoni ...... ts antipsychotic clinical dose
@en
P2093
P2860
P2888
P356
10.1038/TP.2016.195
P577
2016-10-18T00:00:00Z